Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Thoracic Malignancies
•
Medical Oncology
Is there a scenario where you would consider multiple NSCLC lesions in the same lobe as multifocal synchronous malignancies rather than intrapulmonary metastases, (ie, mpT1 rather than T3?
Related Questions
Has the MARS data for mesothelioma changed whether you would recommend surgery for these patients?
Would you consider using IO alone for lung cancer patients who are PDL1 <1 but have high TMB?
What chemotherapy regimens would be appropriate for cisplatin-ineligible patients to receive concurrently with definitive radiotherapy for locally advanced (inoperable) thymic carcinoma?
Would you consider Amivantamab + Lazertinib combo for first line in EGFR mutated metastatic NSCLC, given the recent ESMO updates?
How would you approach a patient with limited stage SCLC who progressed immediately after completing chemoradiation with brain metastasis?
In patients with driver mutation positive NSCLC who have progressed on targeted therapy and are planned for chemotherapy as the next line of treatment, for which driver alterations do you add in IO and which do you omit IO?
Will you consider definitive concurrent chemoradiation for stage IV lung adenocarcinoma with metastasis limited to an internal mammary lymph node?
For patients with biphasic mesothelioma who complete pleurectomy/decortication, would you consider offering adjuvant combination immune checkpoint inhibitor therapy vs. platinum chemotherapy?
What is your preferred first line approach to patients with Stage IV non-squamous NSCLC with good performance status, no driver mutations, PD-L1 low-positive, and CKD IIIB or worse, CrCl < 45 mL/min?
What is your preferred approach for managing oligoprogressive NSCLC during second-line or later systemic therapy if patient is otherwise responding well at other sites of disease?